Trials / Completed
CompletedNCT00126061
Intravenous Tedisamil in the Rapid Conversion of Atrial Fibrillation or Flutter to Normal Sinus Rhythm in Male Subjects
A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel Design Study to Evaluate the Efficacy and Safety of Intravenous Tedisamil Sesquifumarate in the Rapid Conversion to Normal Sinus Rhythm in Male Subjects With Recent Onset Atrial Fibrillation or Flutter
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Solvay Pharmaceuticals · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to demonstrate the ability of tedisamil to convert atrial fibrillation or flutter into normal sinus rhythm (NSR) in male patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tedisamil sesquifumarate |
Timeline
- Start date
- 2004-10-01
- Primary completion
- 2006-01-01
- Completion
- 2006-01-01
- First posted
- 2005-08-02
- Last updated
- 2015-01-16
Locations
26 sites across 5 countries: United States, Czechia, Poland, Russia, Ukraine
Source: ClinicalTrials.gov record NCT00126061. Inclusion in this directory is not an endorsement.